

VSD closure with Lifetech device

QijianYi Heart Center, Children's Hospital Chongqing Medical University Chongqing 400014
China



Objective

To evaluate the safety, effect and complication in children with ventricular septal defect (VSD) closure using Lifetech device.



Methods

- ◆ To retrospectively study VSD patients successfully received transcatheter interventional closure with Lifetech device from May 2004 to April 2010 in Children's Hospital of Chongqing Medical University.
- Complications appeared immediately, 24 hours,1 months,3 months,6 months,1 year follow-up after the procedure were analyzed in all patients by TTE and ECG.



- There were 431 VSD patients fited device closure by Echo, 408 cases closured,19 cases unsuited device closure by angiograhpy,4 cases had serious complications after planted device.
- age from 1 year 6 months to 16 years 3 months (average 5.14±3.22 years),
- igoplus weight from 8kg to 56kg (average 17.54 \pm 7.83kg).




- ◆ The size of VSD from 3.5 mm to 12.1mm (average 5.27±3.04mm) measured by angiography before closure.
- The diameter of VSD occluders from 5mm to 16mm (average 6.50 ± 2.20 mm).



The type of VSD by Echo and angiography

VSD type	number	percentage
Perimembranous	421	98.04%
Supracristal	8	1.47%
Muscular	1	0.25%
VSD after TOF	1	0.25%







The type of VSD occluder


VSD occluder	number	percentage
Symmetric	362	88.73%
Eccentric	23	5.64%
Asymmetric	22	5.39%
Muscular	1	0.25%



HeartR Membranous Symmetic VSD Occluder








HeartR™ Membranous VSD (Symmetric) Occluder Product Specification


Code	D Waist Diameter (mm)	D1 Right Disc Diameter (mm)	D2 Left Disc Diameter (mm)	Waist Length (mm)	Minimum Recommended Sheath Size SteerEase™ (Fr.)	
XJFVM04	4	8	8	3	SFP5F	
XJFVM05	5	9	9	3	SFP5F	
XJFVM06	6	10	10	3	SFP6F	
XJFVM07	7	11	11	3	SFP6F	
XJFVM08	8	12	12	3	SFP7F	
XJFVM10	10	14	14	3	SFP7F	
XJFVM12	12	16	16	3	SFP9F	
XJFVM14	14	19	19	3	SFP9F	
XJFVM16	16	21	21	3	SFP9F	
XJFVM18	18	23	23	3	SFP10F	
XJFVM20	20	25	25	3	SFP10F	
XJFVM22	22	27	27	3	SFP12F	
XJFVM24	24	29	29	3	SFP12F	





HeartR Membranous Eccentric VSD Occluder






HeartR™ Membranous VSD (Eccentric) Occluder Product Specification




Code	D Waist Diameter (mm)	D1 Right Disc Diameter (mm)	D2 Left Disc Diameter (mm)	Waist Length (mm)	Minimum Recommended Sheath Size SteerEase™ (Fr.	
XJFVM04B	4	10	10	3	SFP5F	
XJFVM05B	5	11	11	3	SFP5F	
XJFVM06B	6	12	12	3	SFP6F	
XJFVM07B	7	13	13	3	SFP6F	
XJFVM08B	8	14	14	3	SFP7F	
XJFVM10B	10	16	16	3	SFP7F	
XJFVM12B	12	18	18	3	SFP9F	
XJFVM14B	14	20	20	3	SFP9F	
XJFVM16B	16	22	22	3	SFP9F	
XJFVM18B	18	24	24	3	SFP10F	
XJFVM20B	20	26	26	3	SFP10F	
XJFVM22B	22	28	28	3	SFP12F	
XJFVM24B	24	30	30	3	SFP12F	






HeartR Membranous Asymmetic VSD Occluder











Code	D Waist Diameter (mm)	D1 Right Disc Diameter (mm)	D2 Left Disc Diameter (mm)	Waist Length (mm)	Minimum Recommended Sheath Size SteerEase™ (Fr.) SFP5F	
XJFVM04A II	4	9	11.6	3		
XJFVM05A II	5	10	12.6	3	SFP5F	
XJFVM06A Ⅱ	6	11	13,6	3	SFP6F	
XJFVM07A II	7	12	14.6	3	SFP6F	
XJFVM08A II	8	13	15,6	3	SFP7F	
XJFVM10A Ⅱ	10	15	17.6	3	SFP7F	
XJFVM12A II	12	17	19.6	3	SFP9F	
XJFVM14A Ⅱ	14	19	21.6	3	SFP9F	
XJFVM16A II	16	21	23.6	3	SFP9F	
XJFVM18A II	18	23	25,6	3	SFP10F	
XJFVM20A II	20	25	27.6	3	SFP10F	
XJFVM22A II	22	27	29,6	3	SFP12F	
XJFVM24A II	24	29	31.6	3	SFP12F	





HeartR Muscular VSD Occluder






HeartR[™] Muscular VSD Occluder Product Specification



Code	D Waist Diameter (mm)	D1 Right Disc Diameter (mm)	D2 Left Disc Diameter (mm)	L Waist Length (mm)	Minimum Recommended Sheath Size SteerEase™ (Fr.	
XJFVJ04	4	10	10	7	SFP5F	
XJFVJ05	5	11	11	7	SFP5F	
XJFVJ06	6	12	12	7	SFP5F	
XJFVJ07	7	13	13	7	SFP6F	
XJFVJ08	8	14	14	7	SFP7F	
XJFVJ10	10	16	16	7	SFP7F	
XJFVJ12	12	18	18	7	SFP9F	
XJFVJ14	14	20	20	7	SFP9F	
XJFVJ16	16	22	22	7	SFP9F	
XJFVJ18	18	24	24	7	SFP10F	
XJFVJ20	20	26	26	7	SFP10F	
XJFVJ22	22	28	28	7	SFP12F	
XJFVJ24	24	30	30	7	SFP12F	







Serious complications: 12 patients (2.94%)

- success rate 408/431(94%)
- ◆ 3 cases(0.74%) had Ⅲ° AVB after implanted VSD occluder and recovery by using temporary pacemaker and adrenal cortex hormone for 3~5 days
- ♦ 6 (1.47%) had hemolysis and recovery within 7 days
- 1 (0.25%) had aortic valve clampped by occluder device
- 3 cases(0,74%) happened occluder device displaced and closure by surgery
- no death



Mild complications: 121(29.66%) within 24hrs

	24hrs	1month	3months	6months	s 1year
residual shunt	49(12.01%)	10(2.45%)	7(1.72%)	4(0.98%)	2(0.49%)
pulmonary regurgitation	25(6.13%)	16(3.92%)	9(2.21%)	6(1.47%)	2(0.49%)
aortic regurgitation	10(2.45%)	0	0	0	0
tricuspid regurgitation	13(3.19%)	3(0.74%)	1(0.25%)	0	0
mitral regurgitation	3(0.74%)	0	0	0	0
RBBB	49(12.01%)	16(3.92%)	10(2.45%)	5(1.23%)	3(0.74%)
LBBB	11(2.70%)	3(0.74%)	2(0.49%)	2(0.49%)	2(0.49%)
I ° AVB	5 (1.23%)	1(0.25%)	0	0	0
idionodal rhythm	4(0.98%)	0	0	0	0
Ventricularprematurebea	t 7(1.72%)	0	0	0	0
nodal escape beat	8(1.96%)	0	0	0	0
ventricular escape beat	2(0.49%)	0	0	0	0
junctional escape beat	3(0.74%)	0	0	0	0
sinus bradycardia	1(0.25%)	0	0	0	0



Conclusion

- VSD closure with Lifetech device is a safe, and effective treatment method
- most of mild complications after closed with VSD occluder can be disappeared with time.
- We should strictly decide which CHD suitable for VSD device closure, and choose VSD device according to the shape of VSD by Echo and angiography, and in principle, as small as possible in VSD device closure.



